TBPH Q3 2020 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+46.9% YoY

Gross Profit

$18M100.0% margin

Operating Income

-$77M-419.6% margin

Net Income

-$74M-403.4% margin

EPS (Diluted)

$-1.16

QoQ Revenue Growth

+21.6%

Cash Flow

Operating Cash Flow

-$77M

Free Cash Flow

-$79M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$512M

Total Liabilities

$774M

Stockholders' Equity

-$262M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$12M	+46.9%
Gross Profit	$18M	-$40M	+146.1%
Operating Income	-$77M	-$65M	-17.5%
Net Income	-$74M	-$58M	-26.0%

Revenue Segments

Co Promote Agreement

$11M60%

Collaborative Arrangement Revenue

$7M40%